News
AZ Fasenra shows benefit in chronic rhinosinusitis with nasal polyps
AstraZeneca’s Fasenra (benralizumab) significantly reduced the size of nasal polyps and cut nasal blockage in patients with chronic rhinosinusitis, raising hopes for a new treatment option for this condition.